1) Matsui, T., Li, L., Wu, J. C., Cook, S. A., Nagoshi, T., Picard, M. H., Liao, R. & Rosenzweig, A. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol. Chem., 277: 22896-22901, 2002.
2) Nagoshi, T., Matsui, T., Aoyama, T., Leri, A., Anversa, P., Li, L., Ogawa, W., Del, Monte, F., Gwathmey, J. K., Grazette, L., Hemmings, B., Kass, D. A., Champion, H. C. & Rosenzweig, A. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J. Clin. Invest, 11:5 2128-2138, 2005.
3) Matsui, T., Nagoshi, T., Hong, E. G., Luptak, I., Hartil, K., Li, L., Gorovits, N., Charron, M. J., Kim, J. K., Tian, R. & Rosenzweig, A. Effects of chronic Akt activation on glucose uptake in the heart. Am. J. Physiol. Endocrinol. Metab., 290: E789-E797, 2006.
4) Nagoshi, T., Yoshimura, M., M. C. Rosano G., D. Lopaschuk, G. & Mochizuki, S. Optimization of cardiac metabolism in heart failure. Curr. Pharm. Des., 17: 3846-3853, 2011.